{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:35Z","timestamp":1753891775857,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is rare and aggressive neoplasia, with a poor prognosis; furthermore, the monetary cost of its treatment represents a major challenge for many patients. The economic burden this malignancy imposes is underscored by the fact that asbestos exposure, which is the most frequent risk factor, is much more prevalent in the lower socioeconomic population of developing countries. The aims of the present study were to evaluate the efficacy, safety, and cost of continuous infusion of low-dose Gemcitabine plus Cisplatin (CIGC) as a treatment strategy for patients with unresectable MPM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective cohort study to determine efficacy and safety of continuous infusion gemcitabine at a dose of 250 mg\/m2 in a 6-h continuous infusion plus cisplatin 35 mg\/m2 on days 1 and 8 of a 21-day cycle in patients with unresectable MPM. We also performed a cost-minimization analysis to determine if this chemotherapy regimen is less expensive than other currently used regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median number of chemotherapy cycles was six (range 1\u201311 cycles); objective response rate was documented in 46.2%, and disease control rate was seen in\u00a081.2%. Median PFS was 8.05 months (CI 95% 6.97\u20139.13); median OS was 16.16 months (CI 95% 12.5\u201319.9). The cost minimization analysis revealed savings of 66.4, 61.9, and 97.7% comparing CIGC with short-infusion gemcitabine plus cisplatin (SIGC), cisplatin plus pemetrexed (CP), and cisplatin plus pemetrexed and bevacizumab (CPB), respectively. Furthermore, this chemotherapy regimen proved to be safe at the administered dosage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CIGC is an effective and safe treatment option for patients with unresectable MPM; besides, this combination is a cost-saving option when compared with other frequently used chemotherapy schemes. Therefore, this treatment scheme should be strongly considered for patients with unresectable MPM and limited economic resources.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.641975","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:47:57Z","timestamp":1618940877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma"],"prefix":"10.3389","volume":"11","author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Mu\u00f1oz-Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Mu\u00f1iz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Soto-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Guzm\u00e1n V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo","family":"D\u00edaz-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Mart\u00ednez-Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny G.","family":"Turcott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritza","family":"Ramos-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Cabrera-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feliciano","family":"Barr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2429-5","article-title":"A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma","volume":"73","author":"Arrieta","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2016-104173","article-title":"The economic burden of lung cancer and mesothelioma due to occupational and para-occupational asbestos exposure","volume":"74","author":"Tompa","year":"2017","journal-title":"Occup Environ Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.20780","article-title":"Control study of pleural mesothelioma in workers with social security in Mexico","volume":"53","author":"Aguilar-Madrid","year":"2009","journal-title":"Am J Ind Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000174","article-title":"Modern Management of Malignant Pleural Effusions","volume":"23","author":"Mercer","year":"2016","journal-title":"Clin Pulm Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12094-008-0163-3","article-title":"Can the Spanish care system assume the new costs of medications against cancer","volume":"10","author":"Camps","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.19","article-title":"Chemotherapy treatment in malignant pleural mesothelioma: A difficult history","volume":"10","author":"Cinausero","year":"2018","journal-title":"J Thorac Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future","volume":"9","author":"Nicolini","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet 30"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.11.003","article-title":"Surgical management of malignant pleural mesothelioma: A systematic review and evidence summary","volume":"48","author":"Maziak","year":"2005","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading","volume":"10","author":"Cantini","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients with Malignant Pleural Mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.027","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J. Natl. Compr","volume":"14","author":"Ettinger","year":"2016","journal-title":"Cancer Netw"},{"key":"B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","article-title":"The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute J","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1524-4733.2007.00209.x","article-title":"Cost-effectiveness of pemetrexed plus cisplatin: Malignant pleural mesothelioma treatment in UK clinical practice","volume":"11","author":"Cordony","year":"2008","journal-title":"Value Heal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10937404.2016.1195323","article-title":"Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States","volume":"19","author":"Lemen","year":"2016","journal-title":"J Toxicol Environ Heal Part B"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32834d7a1c","article-title":"A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma","volume":"23","author":"Kovac","year":"2012","journal-title":"Anticancer Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study","volume":"17","author":"Byrne","year":"1999","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.09.018","article-title":"Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)","volume":"60","author":"Kalmadi","year":"2008","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600505","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak","year":"2002","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000144852.75613.56","article-title":"Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study","volume":"28","author":"de Gooijer","year":"2018","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005817024382","article-title":"Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg\/m2) and high-dose (875 mg\/m2) levels","volume":"15","author":"Pollera","year":"1997","journal-title":"Invest New Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0959-8049(01)00127-7","article-title":"EORTC QLQ-C30 Scoring Manual the EORTC QLQ-C30 Introduction","volume":"30","author":"Fayers","year":"2001","journal-title":"EORTC QLQ-C30 Scoring Man"},{"key":"B32","first-page":"1","volume-title":"Cuadro B\u00e1sico y Cat\u00e1logo de Insumos del Sector Salud en M\u00e9xico","author":"Comisi","year":"2017"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Heal"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1007\/978-84-940346-6-4","article-title":"Evaluaci\u00f3n econ\u00f3mica de medicamentos y tecnolog\u00edas sanitarias","volume-title":"Evaluaci\u00f3n econ\u00f3mica de medicamentos y tecnolog\u00edas sanitarias","author":"Soto \u00c1lvarez","year":"2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2036361319863498","DOI":"10.1177\/2036361319863498","article-title":"Costs of medical care for mesothelioma","volume":"11","author":"Borrelli","year":"2019","journal-title":"Rare Tumors"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic Factors in Patients with Pleural Mesothelioma: The European Organization for Research and Treatment of Cancer Experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine\/Cisplatin Plus Bevacizumab or Placebo in Patients with Malignant Mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00520-005-0837-0","article-title":"Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): Psychometric properties of the LCSS-Meso. Support","volume":"14","author":"Hollen","year":"2006","journal-title":"Care Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.641975\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:48:01Z","timestamp":1618940881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.641975\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":39,"alternative-id":["10.3389\/fonc.2021.641975"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.641975","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"article-number":"641975"}}